BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...

Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
Monmouth, NJ, (May 22, 2009) -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRXTM Antibacterial Envelope Retrospective Registry.
© 2026 Pappas Capital, LLC. ALL RIGHTS RESERVED.